FINANCE/FUNDING ARTICLES

• Key Questions To Ask When Entering A Pharma Partnership

  Before entering a partnership, executives need to ask themselves and their prospective partners’ key questions in the following five areas:

• Explaining Private Equity’s Increased Appetite For Drug Development

  In recent years, private equity firms have shown a growing interest in pharmaceutical drug development. So, why is private equity making investments that resemble those of VC firms?

• A Recipe For Start-Up Success With A Platform Technology

  Platform companies face a fundamental problem — how to return money to investors in a reasonable time frame and simultaneously realize the appropriate value for their platform. Here’s one approach that worked.

• Anatomy Of A Biopharma VC Deal

  Ray Therapeutics CEO Paul Bresge and 4BIO Capital Managing Partner Dmitri Kuzmin, Ph.D. break down the deal that launched Ray and ponder the risk of a mission-driven biopharma CEO.

• Will The Finance And Funding Pendulum Swing Back To Black In 2023?

  Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

• Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

  The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.

• 5 Steps To Avoid Mismanaging Biopharma Grant Funds

  Here’s how to ensure you’re successfully maximizing that infusion of money and setting yourself up for further success in the grant world.

• What Has Changed With The R&D Tax Credit?

  : The R&D tax credit, an often overlooked and misunderstood opportunity for taxpayers, can be used to offset the cost of drug discovery.

• In A Tighter VC Environment, Biopharmas Need To Get Valuation Right

  The rigor investors are demanding from emerging companies means that life sciences entrepreneurs need to double down on having clear and concise milestones and good strategic plans — a challenging proposition, especially for early-stage companies that typically do not have suitable market comparisons.

• Milestone Payments In Life Sciences M&A And Licensing Transactions

  Now is an opportune time to take a fresh look at some key considerations regarding a common feature of M&As — payments that become due in the future upon the achievement of specified events, which are commonly known as “milestones.”